Abstract 192P
Background
Studies of apatinib monotherapy suggest that ARAE (proteinuria, hand-foot syndrome [HFS] and hypertension) may predict clinical outcomes in patients with AGC; however, this phenomenon has not been reported in patients receiving apatinib + chemotherapy. We evaluated the potential association between ARAE and efficacy outcomes of apatinib +chemotherapy for AGC.
Methods
We reviewed two prospective trials of patients treated with apatinib + chemotherapy (POF or paclitaxel alone), a phase II study (ESMO-ASIA 2018) and a phase I study (ESMO 2022). POF was paclitaxel 135 mg/m2 over 3 h followed by leucovorin 400 mg/m2 and oxaliplatin 85 mg/m2 over 2 h; then 5-FU 2,400 mg/m2 continuous infusion over 46 h. Drugs were started days 1 and 15 of each 28-day cycle. Paclitaxel alone was 80 mg/m2 days 1, 8, and 15 of every 28-day cycle. Presence of any ARAE in the first 4 weeks of therapy was assessed and the primary outcome was overall survival (OS). OS was estimated using Kaplan-Meier with the log-rank test. Hazard ratios (HRs) were calculated by univariate and multivariate Cox proportional regression models.
Results
The number of participants was 43 (POF, n=41; paclitaxel alone, n=2). In the first 4 weeks of treatment, 22 (51.2%) had any grade proteinuria, 13 (30.0%) had any grade HFS, and 14 (32.6%) had any grade hypertension. The presence of proteinuria or HFS was associated with prolonged median OS ([months] proteinuria 5.93 vs. 19.10; HR 0.40, 95% CI 0.20-0.79; P=0.0065; HFS 8.92 vs. 22.57 ; HR 0.48, 95% CI 0.23-0.98; P=0.04) and progression-free survival ([PFS] proteinuria 3.50 vs. 9.60 ; HR 0.46, 95% CI 0.23-0.91; P=0.022; HFS 6.40 vs. 10.67 ; HR 0.54, 95% confidence interval (CI) 0.27-1.07; P=0.073 ). 24 (55.8%) patients had one (any grade) proteinuria or HFS in the first 4 weeks, which was associated with prolonged median OS (6.77 vs. 16.35 ; HR 0.47, 95% CI 0.24-0.93; P=0.031) and PFS (4.20 vs. 8.75; HR 0.55, 95% CI 0.28-1.08; P=0.080).
Conclusions
Antiangiogenesis-related proteinuria and HFS may be biomarkers to predict antitumor efficacy of apatinib + chemotherapy in AGC. Future prospective studies are needed to validate findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract